IMC Chicago’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $27.1M | Buy |
147,700
+15,300
| +12% | +$2.82M | 0.01% | 730 |
|
|
2025
Q4 | $23.3M | Buy |
132,400
+21,400
| +19% | +$3.5M | 0.01% | 778 |
|
|
2025
Q3 | $15.5M | Buy |
111,000
+9,000
| +9% | +$1.22M | 0.01% | 900 |
|
|
2025
Q2 | $12.8M | Buy |
102,000
+17,100
| +20% | +$2.13M | 0.01% | 907 |
|
|
2025
Q1 | $11.6M | Buy |
84,900
+59,700
| +237% | +$8.53M | 0.01% | 825 |
|
|
2024
Q4 | $3.85M | Buy |
25,200
+6,700
| +36% | +$1.13M | ﹤0.01% | 1410 |
|
|
2024
Q3 | $3.59M | Buy |
18,500
+2,100
| +13% | +$439K | ﹤0.01% | 1310 |
|
|
2024
Q2 | $3.8M | Buy |
16,400
+1,700
| +12% | +$369K | ﹤0.01% | 1189 |
|
|
2024
Q1 | $3.17M | Sell |
14,700
-17,800
| -55% | -$4.17M | ﹤0.01% | 1147 |
|
|
2023
Q4 | $8.41M | Buy |
32,500
+1,500
| +5% | +$368K | 0.01% | 711 |
|
|
2023
Q3 | $7.97M | Sell |
31,000
-100
| -0.3% | -$26.7K | 0.01% | 615 |
|
|
2023
Q2 | $8.86M | Sell |
31,100
-12,700
| -29% | -$3.78M | 0.01% | 533 |
|
|
2023
Q1 | $12.2M | Sell |
43,800
-84,500
| -66% | -$23.4M | 0.01% | 439 |
|
|
2022
Q4 | $35.5M | Sell |
128,300
-67,300
| -34% | -$19M | 0.06% | 209 |
|
|
2022
Q3 | $52.2M | Buy |
195,600
+122,400
| +167% | +$26M | 0.07% | 134 |
|
|
2022
Q2 | $14.9M | Buy |
73,200
+48,800
| +200% | +$9.98M | 0.02% | 353 |
|
|
2022
Q1 | $5.14M | Sell |
24,400
-72,000
| -75% | -$15.7M | 0.01% | 566 |
|
|
2021
Q4 | $23.1M | Sell |
96,400
-19,200
| -17% | -$4.94M | 0.02% | 341 |
|
|
2021
Q3 | $32.7M | Sell |
115,600
-56,500
| -33% | -$18.5M | 0.03% | 254 |
|
|
2021
Q2 | $59.6M | Buy |
172,100
+105,200
| +157% | +$31.9M | 0.07% | 144 |
|
|
2021
Q1 | $18.7M | Sell |
66,900
-251,500
| -79% | -$67.8M | 0.03% | 307 |
|
|
2020
Q4 | $78M | Buy |
318,400
+257,300
| +421% | +$66.4M | 0.1% | 92 |
|
|
2020
Q3 | $17.3M | Sell |
61,100
-30,600
| -33% | -$8.53M | 0.03% | 231 |
|
|
2020
Q2 | $24.5M | Buy |
91,700
+57,000
| +164% | +$17.1M | 0.05% | 131 |
|
|
2020
Q1 | $11M | Sell |
34,700
-47,100
| -58% | -$14.3M | 0.02% | 204 |
|
|
2019
Q4 | $24.3M | Buy |
81,800
+27,100
| +50% | +$7.52M | 0.06% | 106 |
|
|
2019
Q3 | $12.7M | Sell |
54,700
-17,300
| -24% | -$4.03M | 0.04% | 152 |
|
|
2019
Q2 | $16.8M | Sell |
72,000
-123,600
| -63% | -$28.5M | 0.05% | 116 |
|
|
2019
Q1 | $46.2M | Buy |
195,600
+176,200
| +908% | +$55.5M | 0.17% | 39 |
|
|
2018
Q4 | $5.84M | Buy |
+19,400
| New | +$6.19M | 0.02% | 176 |
|
Other funds holding BIIB
VCM
VPM
IMC Chicago's BIIB Position: Q1 2026 in Review
IMC Chicago sold out of Biogen (BIIB) in Q1 2026, closing a stake of 19,011 shares — an estimated $3.5M sold.
IMC Chicago first reported a position in BIIB in Q4 2020 and held it in 5 quarters. The position peaked at $8.45M in Q2 2021. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- IMC Chicago reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
- IMC Chicago sold 19,011 Biogen shares in Q1 2026, an estimated $3.5M.
- IMC Chicago first reported a position in Biogen in Q4 2020 and held it in 5 quarters.
- IMC Chicago's Biogen position peaked at $8.45M in Q2 2021.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.